Conference Coverage
Conference Coverage
Tirzepatide with insulin glargine improves type 2 diabetes
“Demonstrating superiority over insulin lispro in terms of the so-called trio of A1c, weight loss, and hypoglycemic events, tirzepatide offers...
Conference Coverage
Menstruation linked to underdiagnosis of type 2 diabetes?
The analysis estimates that an additional 17% of undiagnosed women younger than 50 years could be reclassified as having type 2 diabetes.
Conference Coverage
Screening finds high rates of CVD in diabetes, COPD patients
The study tested a “very simple” symptom questionnaire as the initial screening phase, yet resulted in a CVD diagnostic rate that was two- to...
Conference Coverage
ESC backs SGLT2 inhibitor plus GLP-1 in diabetes with high CVD risk
Another major change in the new ESC guideline revision is introduction of a CVD risk calculator intended to estimate the risk among people with...
Conference Coverage
Growth hormone links with worse T2D control in adolescents
Researchers hope to “leverage these data to find predictive markers” that could identify adolescents with type 2 diabetes “at risk for...
Conference Coverage
Studies link GLP-1 agonists to progression of diabetic retinopathy
“The strength of these effects depends on the specific GLP-1 receptor agonist used, patient-specific clinical characteristics, and demographics...
News
Time-restricted eating gains for weight and glycemic control
While no evidence clearly shows that 8 hours is the best eating-window duration, “we think 8 hours is a good sweet-spot for motivated people.”
Conference Coverage
Semaglutide use surges in U.S. adults with type 2 diabetes
“The market share of GLP-1 agonists is likely to expand in patients with type 2 diabetes,” especially those who also have obesity.
Conference Coverage
Intermittent fasting vs. calorie counting for weight loss
“If you’ve tried calorie counting, that’s not working for you or if you’re kind of burnt out, this is something else that you could try.”
Conference Coverage
Debate: Initial combination therapy for type 2 diabetes?
Ralph A. DeFronzo, MD, argued for combination therapy at the time of diagnosis, and David M. Nathan, MD, countered that sequential therapy is a...